Rafael Sánchez-Sánchez

Rafael Sánchez-Sánchez

Auto-generated profile, based on publicly available information

Rafael Sánchez-Sánchez

Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2014 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
ÁSÁlvaro Sánchez-Ferro
Álvaro Sánchez-Ferro
ARAlberto Rábano
Alberto Rábano
MCMaría José Catalán
María José Catalán
FRFernando Canga Rodríguez‐Valcárcel
Fernando Canga Rodríguez‐Valcárcel
SDServando Fernández Díez
Servando Fernández Díez
JMJosé Antonio Molina‐Arjona
José Antonio Molina‐Arjona

1 November 2020 in Brain
Verified
Journal Article
Open access
PDF file
Antonio Carlos Fuentes-FayosAntonio Carlos Fuentes-Fayos
Antonio Carlos Fuentes-Fayos
MVMari C Vázquez-Borrego
Mari C Vázquez-Borrego
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
LBLeire Bejarano
Leire Bejarano
SPSergio Pedraza-Arevalo
Sergio Pedraza-Arevalo
Raul LuqueRaul Luque
Raul Luque
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12–16-month survival from diagnosis. Therefore, identification of new diagnostic, prognostic and therapeutic tools to tackle glioblastomas is urgently needed. Emerging evidence indicates that the cellular machinery controlling the splicing process (spliceosome) is altered in tumours, leading to oncogenic splicing events associated with tumour progression and aggressiveness. Here, we identify for the first time a profound dysregulation in the expression of relevant spliceosome components and splicing factors (at mRNA and protein levels) in well characterized cohorts of human high-grade astrocytomas, mostly glioblastomas, compared to healthy brain control samples, being SRSF3, RBM22, PTBP1 and RBM3 able to perfectly discriminate between tumours and control samples, and between proneural-like or mesenchymal-like tumours versus control samples from different mouse models with gliomas. Results were confirmed in four additional and independent human cohorts. Silencing of SRSF3, RBM22, PTBP1 and RBM3 decreased aggressiveness parameters in vitro (e.g. proliferation, migration, tumorsphere-formation, etc.) and induced apoptosis, especially SRSF3. Remarkably, SRSF3 was correlated with patient survival and relevant tumour markers, and its silencing in vivo drastically decreased tumour development and progression, likely through a molecular/cellular mechanism involving PDGFRB and associated oncogenic signalling pathways (PI3K-AKT/ERK), which may also involve the distinct alteration of alternative splicing events of specific transcription factors controlling PDGFRB (i.e. TP73). Altogether, our results demonstrate a drastic splicing machinery-associated molecular dysregulation in glioblastomas, which could potentially be considered as a source of novel diagnostic and prognostic biomarkers as well as therapeutic targets for glioblastomas. Remarkably, SRSF3 is directly associated with glioblastoma development, progression, aggressiveness and patient survival and represents a novel potential therapeutic target to tackle this devastating pathology.

1 October 2019 in Translational Research
Verified
Journal Article
Closed access
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
VHVicente Herrero-Aguayo
Vicente Herrero-Aguayo
EGEnrique Gomez Gomez
Enrique Gomez Gomez
ALAntonio J. León-González
Antonio J. León-González
PSPrudencio Sáez-Martínez
Prudencio Sáez-Martínez
Raul LuqueRaul Luque
Raul Luque

22 March 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MRMercedes del Río-Moreno
Mercedes del Río-Moreno
EAEmilia Alors-Pérez
Emilia Alors-Pérez
SGSandra González-Rubio
Sandra González-Rubio
GFGustavo Ferrín
Gustavo Ferrín
OROscar Reyes
Oscar Reyes
Raul LuqueRaul Luque
Raul Luque
Context Nonalcoholic fatty liver disease (NAFLD) is a common obesity-associated pathology characterized by hepatic fat accumulation, which can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Obesity is associated with profound changes in gene-expression patterns of the liver, which could contribute to the onset of comorbidities. Objective As these alterations might be linked to a dysregulation of the splicing process, we aimed to determine whether the dysregulation in the expression of splicing machinery components could be associated with NAFLD. Participants We collected 41 liver biopsies from nonalcoholic individuals with obesity, with or without hepatic steatosis, who underwent bariatric surgery. Interventions The expression pattern of splicing machinery components was determined using a microfluidic quantitative PCR-based array. An in vitro approximation to determine lipid accumulation using HepG2 cells was also implemented. Results The liver of patients with obesity and steatosis exhibited a severe dysregulation of certain splicing machinery components compared with patients with obesity without steatosis. Nonsupervised clustering analysis allowed the identification of three molecular phenotypes of NAFLD with a unique fingerprint of alterations in splicing machinery components, which also presented distinctive hepatic and clinical-metabolic alterations and a differential response to bariatric surgery after 1 year. In addition, in vitro silencing of certain splicing machinery components (i.e., PTBP1, RBM45, SND1) reduced fat accumulation and modulated the expression of key de novo lipogenesis enzymes, whereas conversely, fat accumulation did not alter spliceosome components expression. Conclusion There is a close relationship between splicing machinery dysregulation and NAFLD development, which should be further investigated to identify alternative therapeutic targets.

29 August 2017 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
DHDaniel Hormaechea-Agulla
Daniel Hormaechea-Agulla
Manuel D. GaheteManuel D. Gahete
Manuel D. Gahete
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
EGEnrique Gomez Gomez
Enrique Gomez Gomez
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
Raul LuqueRaul Luque
Raul Luque
The Ghrelin-system is a complex, pleiotropic family composed of several peptides, including native-ghrelin and its In1-ghrelin splicing variant, and receptors (GHSR 1a/b), which are dysregulated in various endocrine-related tumors, where they associate to pathophysiological features, but the presence, functional role, and mechanisms of actions of In1-ghrelin splicing variant in prostate-cancer (PCa), is completely unexplored. Herein, we aimed to determine the presence of key ghrelin-system components (native-ghrelin, In1-ghrelin, GHSR1a/1b) and their potential pathophysiological role in prostate cancer (PCa). In1-ghrelin and native-ghrelin expression was evaluated by qPCR in prostate tissues from patients with high PCa-risk (n = 52; fresh-tumoral biopsies), and healthy-prostates (n = 12; from cystoprostatectomies) and correlated with clinical parameters using Spearman-test. In addition, In1-ghrelin and native-ghrelin was measured in plasma from an additional cohort of PCa-patients with different risk levels (n = 30) and control-healthy patients (n = 20). In vivo functional (proliferation/migration) and mechanistic (gene expression/signaling-pathways) assays were performed in PCa-cell lines in response to In1-ghrelin and native-ghrelin treatment, overexpression and/or silencing. Finally, tumor progression was monitored in nude-mice injected with PCa-cells overexpressing In1-ghrelin, native-ghrelin and empty vector (control). In1-ghrelin, but not native-ghrelin, was overexpressed in high-risk PCa-samples compared to normal-prostate (NP), and this expression correlated with that of PSA. Conversely, GHSR1a/1b expression was virtually absent. Remarkably, plasmatic In1-ghrelin, but not native-ghrelin, levels were also higher in PCa-patients compared to healthy-controls. Furthermore, In1-ghrelin treatment/overexpression, and to a much lesser extent native-ghrelin, increased aggressiveness features (cell-proliferation, migration and PSA secretion) of NP and PCa cells. Consistently, nude-mice injected with PC-3-cells stably-transfected with In1-ghrelin, but not native-ghrelin, presented larger tumors. These effects were likely mediated by ERK1/2-signaling activation and involved altered expression of key oncogenes/tumor suppressor genes. Finally, In1-ghrelin silencing reduced cell-proliferation and PSA secretion from PCa cells. Altogether, our results indicate that In1-ghrelin levels (in tissue) and circulating levels (in plasma) are increased in PCa where it can regulate key pathophysiological processes, thus suggesting that In1-ghrelin may represent a novel biomarker and a new therapeutic target in PCa.

13 July 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DHDaniel Hormaechea‐Agulla
Daniel Hormaechea‐Agulla
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
EGEnrique Gomez Gomez
Enrique Gomez Gomez
FLFernando L.‐ López
Fernando L.‐ López
JCJulia Carrasco‐Valiente
Julia Carrasco‐Valiente
Raul LuqueRaul Luque
Raul Luque
Sst5TMD4, a splice variant of the sst5 gene, is overexpressed and associated with aggressiveness in various endocrine‐related tumors, but its presence, functional role, and mechanisms of actions in prostate cancer (PCa)—the most common cancer type in males—is completely unexplored. In this study, formalin‐fixed, paraffin‐embedded prostate pieces from patients with localized PCa, which included tumoral and nontumoral adjacent regions ( n = 45), fresh biopsies from patients with high‐risk PCa ( n = 52), and healthy fresh prostates from cystoprostatectomies ( n = 14) were examined. In addition, PCa cell lines and xenograft models were used to determine the presence and functional role of sst5TMD4. Results demonstrated that sst5TMD4 is overexpressed (mRNA/protein) in PCa samples, and this is especially drastic in metastatic and/or high Gleason score tumor samples. Remarkably, sst5TMD4 expression was associated with an altered frequency of 2 single‐nucleotide polymorphisms: rs197055 and rs12599155. In addition, PCa cell lines and xenograft models were used to demonstrate that sst5TMD4 overexpression increases cell proliferation and migration in PCa cells and induces larger tumors in nude mice, whereas its silencing decreased proliferation and migration. Remarkably, sst5TMD4 overexpression activated multiple intracellular pathways (ERK/JNK, MYC/MAX, WNT, retinoblastoma), altered oncogenes and tumor suppressor gene expression, and disrupted the normal response to somatostatin analogs in PCa cells. Altogether, we demonstrate that sst5TMD4 is overexpressed in PCa, especially in those patients with a worse prognosis, and plays an important pathophysiologic role in PCa, which suggesting its potential as a biomarker and/or therapeutic target.—Hormaechea‐Agulla, D., Jiménez‐Vacas, J. M., Gómez‐Gómez, E., L.‐López, F., Carrasco‐Valiente, J., Valero‐Rosa, J., Moreno, M. M., Sánchez‐Sánchez, R., Ortega‐Salas, R., Gracia‐Navarro, F., Culler, M. D., Ibáñez‐Costa, A., Gahete, M. D., Requena, M. J., Castaño, J. P., Luque, R. M. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB J. 31, 4682–4696 (2017). www.fasebj.org